🔴 Spero Therapeutics is trading 21.1% down today despite no clear company-specific catalyst

Spero Therapeutics is trading at $1.72 (-21.10%) following a sharp intraday decline that lacks a fresh company-specific announcement.

• The move comes amid broader weakness in the biotech sector, with the XBI falling 2.45% as investors engage in profit-taking across the space.
• While the sector-wide pullback is a contributing factor, it does not fully explain the significant magnitude of the drop in Spero's share price.
• There are no new regulatory or clinical updates in the feed to justify the move, with the most recent news being an older licensing update.